Howard Weintraub

3 weeks ago | healio.com | Regina Schaffer |Erik Swain |Howard Weintraub |Darren McGuire

Oral semaglutide cuts risk for heart events by 14% in high-risk type 2 diabetes• Oral semaglutide reduced risk for cardiovascular events in people with type 2 diabetes, atherosclerotic CVD and kidney disease. • It is now the first and only oral GLP-1 receptor agonist with proven CV benefit.

Aug 8, 2023 | healio.com | Regina Schaffer |Richard Smith |Howard Weintraub

Source/Disclosures Disclosures: Lange is an employee of Novo Nordisk. Weintraub reports serving as an investigator in the SELECT trial and receiving consultant fees from Novo Nordisk. We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

Mar 16, 2023 | social.cn1699.com | Howard Weintraub

Source/DisclosuresPublished by: Source: Ridker PM, et al. Featured Clinical Research III. Presented at: American College of Cardiology Scientific Session; March 4-6, 2023; New Orleans (hybrid meeting).

Mar 4, 2023 | social.cn1699.com | Howard Weintraub

Source/DisclosuresPublished by: Source: Nissen SE, et al. Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials. Presented at: American College of Cardiology Scientific Session; March 4-6, 2023; New Orleans (hybrid meeting). Disclosures: The CLEAR Outcomes trial was sponsored by Esperion Therapeutics.

Feb 14, 2023 | notiulti.com | Howard Weintraub

14 de febrero de 2023 3 minutos de lectura Fuente/Divulgaciones Divulgaciones: Los autores no informan divulgaciones financieras relevantes. No pudimos procesar su solicitud. Por favor, inténtelo de nuevo más tarde.